Loading...
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committees
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact
  • Listing Nasdaq 2022

Synact in Media

2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
July 12, 2022

Listing ceremony Nasdaq Stockholm

June 9, 2022

Presentation at BioStock Life Science Spring Summit

June 1, 2022

Presentation at Life Science Investor Konference, June 1, 2022 – Copenhagen

May 2, 2022

Presentation at Aktiedagen Stockholm May 2, 2022

April 25, 2022

Presentation at Sedermeradagen April 25, 2022

April 6, 2022

BioStock: SynAct Pharma’s CEO on the rights issue and partnering discussions

March 28, 2022

Interview with Direct Studios

March 28, 2022

Presentation regarding the Rights Issue 2022

February 14, 2022

BioStock: SynAct Pharma well positioned for an eventful 2022

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • Listing Nasdaq 2022
  • LinkedIn

Subscribe